The estimated Net Worth of William A Iii Hockett is at least $963 Thousand dollars as of 8 September 2008. William Hockett owns over 28,447 units of Myriad Genetics stock worth over $557,267 and over the last 22 years William sold MYGN stock worth over $405,407.
William has made over 13 trades of the Myriad Genetics stock since 2004, according to the Form 4 filled with the SEC. Most recently William exercised 28,447 units of MYGN stock worth $843,454 on 8 September 2008.
The largest trade William's ever made was exercising 84,151 units of Myriad Genetics stock on 3 May 2007 worth over $1,464,227. On average, William trades about 6,638 units every 60 days since 2003. As of 8 September 2008 William still owns at least 21,205 units of Myriad Genetics stock.
You can see the complete history of William Hockett stock trades at the bottom of the page.
William's mailing address filed with the SEC is , , , , .
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: